Recent news highlights positive clinical trial results for Mirum's therapies in rare diseases, regulatory approvals, and ongoing Phase 3 studies supporting potential filings.

• Mirum reported positive results for ATEBRIOZ in reducing bone lesion volume in younger children with fibrodysplasia ossificans progressiva (FOP) [N1].
• LIVMARLI met key endpoints in Phase 3 studies for rare liver diseases, with plans for FDA filing in 2027 [N3][N4][N5].
• Brelovitug achieved Phase 3 endpoints in chronic hepatitis delta virus studies and is progressing in global registrational trials [N6].
• Mirum secured FDA approval for an ultra-rare bone disorder therapy, expanding its rare disease portfolio [N7].
• Weekly industry updates noted Mirum among companies scoring FDA wins and advancing clinical programs [N2][N7].
• Mirum's Q4 earnings report detailed financial performance and key metrics compared to prior periods [N8].

Mirum has demonstrated clinical progress with positive Phase 3 results for LIVMARLI and brelovitug, supporting regulatory filings and potential market expansion. Its acquisition strategy and pipeline diversification into rare liver diseases, hepatitis D, and fragile X syndrome provide multiple avenues for growth. The company's strong cash position and liquidity ratios support ongoing development and commercialization efforts. Successful market acceptance of approved medicines and favorable reimbursement could enhance revenue generation.

Risks include challenges in scaling and maintaining sales and marketing capabilities across multiple geographies, potential delays or failures in clinical development, and uncertainties in obtaining and maintaining adequate reimbursement. Competition from generics, compounded drugs, and alternative therapies may impact market share. Pricing pressures and regulatory changes in the US and EU could affect profitability. Adverse side effects or safety concerns may limit commercial uptake or lead to regulatory restrictions.

Mirum's moat derives from its focus on rare and ultra-rare diseases with high unmet medical need, where approved therapies are limited or absent. Its portfolio includes FDA and EMA-approved medicines with orphan drug designations, supported by specialized commercial teams and licensing partnerships. The company's clinical pipeline targets additional rare indications with potential regulatory designations such as Breakthrough Therapy and PRIME, which may facilitate expedited development and approval. Barriers include the complexity of rare disease markets, regulatory hurdles, and the need for specialized sales and distribution capabilities.

• Commercialization Risks: Mirum's ability to profitably market approved medicines depends on scaling sales teams, distribution capabilities, reimbursement availability, and physician and patient acceptance. Failure in any area could delay or reduce revenues [Q0-Q2].
• Reimbursement and Pricing Pressure: Coverage and reimbursement vary by payor and geography, with increasing cost containment efforts, government negotiations, and regulatory changes potentially limiting pricing and access [Q2-Q6].
• Market Acceptance: Physician and patient willingness to adopt Mirum's therapies depends on perceived efficacy, safety, convenience, and competition from existing or future treatments [Q7-Q8].
• Safety and Side Effects: Adverse events observed in clinical trials, including gastrointestinal symptoms and vitamin deficiencies, may affect patient adherence and regulatory labeling [Q9].
• Regulatory and Development Risks: Clinical trial outcomes, regulatory approvals, and potential delays or failures in pipeline development pose risks to future product launches and revenue streams [S1].

• Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases with three approved medicines: LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol) [S1].
• LIVMARLI is an orally administered IBAT inhibitor approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) in the US, EU, Canada, and Japan, commercialized directly in US, Canada, and parts of Europe, with licensing agreements for other territories [S1].
• CHOLBAM is FDA-approved for bile acid synthesis disorders and adjunctive treatment of peroxisomal disorders including PBD-ZSD, commercialized in the US [S1].
• CTEXLI (chenodiol) is FDA-approved for cerebrotendinous xanthomatosis (CTX) and commercialized in the US [S1].
• Mirum acquired assets related to chenodiol and Cholbam from Travere Therapeutics in August 2023 [S1].
• Mirum is advancing product candidates including volixibat (oral IBAT inhibitor) for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), with Phase 2b trials ongoing and topline data expected in 2026 [S1].
• Brelovitug (BJT-778), acquired via Bluejay Therapeutics acquisition in January 2026, is a monoclonal antibody for chronic hepatitis D virus (HDV) infection, with FDA Breakthrough Therapy and EMA PRIME designations, in Phase 3 AZURE clinical program with topline results expected in second half of 2026 [S1].
• MRM-3379 is a novel oral PDE4D inhibitor in Phase 2 for fragile X syndrome (FXS), with topline data anticipated in 2027 [S1].
• Mirum's strategy includes commercializing approved medicines, advancing clinical programs to regulatory approval, acquiring additional rare disease products, and deploying resources efficiently for long-term value creation [S1].
• The company reported cash and equivalents of $243.2 million and short-term investments of $130.5 million as of September 30, 2026, with current assets of $586.6 million and current liabilities of $283.1 million, yielding a current ratio of 2.07 and cash ratio of 1.32 [S2].
• Net loss for the nine months ended September 30, 2026, was $40.8 million with basic and diluted EPS of -$0.62 and -$0.87 respectively [S2].
• Mirum reported positive Phase 3 results for LIVMARLI in rare liver diseases and plans FDA filing in 2027 [N3][N4][N5].
• Brelovitug met Phase 3 endpoints in chronic hepatitis delta studies and is in ongoing registrational trials [N6].
• Mirum's ATEBRIOZ showed reduction in bone lesion volume in younger children with fibrodysplasia ossificans progressiva (FOP) [N1].
• The company has received FDA approvals for therapies targeting ultra-rare diseases including ALGS, PFIC, CTX, and bile acid synthesis disorders [S1][N7].
• Mirum's commercial efforts include a specialized sales team in the US, Canada, and parts of Europe, with partnerships for distribution in other territories [S1][Q1].
• Risks include challenges in scaling sales and marketing capabilities, obtaining adequate reimbursement, competition from generics and compounded drugs, limited patient populations, and potential adverse side effects impacting market acceptance [Q0-Q9].
• Side effects reported for LIVMARLI include diarrhea, abdominal pain, vomiting, and fat-soluble vitamin deficiency; volixibat trials reported mild to moderate gastrointestinal events [Q9].
• Pricing and reimbursement pressures exist in the US and EU markets, including government regulations, cost containment efforts, and evolving health technology assessments [Q2-Q6].